<DOC>
	<DOC>NCT00612027</DOC>
	<brief_summary>Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. general practitioners and internists) are asked to document relevant data related to esomeprazole therapy in patients with gastrointestinal disorders. Patients with acid associated gastrointestinal symptoms can be included.</brief_summary>
	<brief_title>Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole. limitiations; possible risks; warnings; contraindications mentioned in the SPC.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>acid associated gastrointestinal symptoms.</keyword>
	<keyword>esomeprazole therapy in patients with gastrointestinal disorders</keyword>
	<keyword>patients with acid associated gastrointestinal symptoms</keyword>
</DOC>